PNU-292137
PNU-292137 is an orally active, potent CDK2 inhibitor with IC50s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model[1].
Product Specifications
CAS Number
[326823-27-2]
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pnu-292137.html
Purity
99.95
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CC1=CC=C2C=CC=CC2=C1)NC3=NNC(C4CC4)=C3
Molecular Formula
C18H17N3O
Molecular Weight
291.35
References & Citations
[1]Paolo Pevarello, et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J Med Chem. 2004 Jun 17;47 (13) :3367-80.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK4; CDK5
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Cgref1 (Cell Growth Regulator with EF hand Domain Protein 1, Cell Growth Regulatory gene 11 Protein, Hydrophobestin, Cgref1, Cgr11) (FITC)
Cgref1 (Cell Growth Regulator with EF hand Domain Protein 1, Cell Growth Regulatory gene 11 Protein, Hydrophobestin, Cgref1, Cgr11) (FITC)
![Rabbit Polyclonal SLITRK1 Antibody [Alexa Fluor 647]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
Lentiviral human SLC22A13 sgRNA gene knockout kit - Lentiviral human SLC22A13 sgRNA gene knockout kit (plasmid)